foxo4 dri peptide senolytic human trial FOXO4-DRI UK | Research The disordered p53 transactivation domain
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI: The Senolytic Peptide That Targets Zombie Cells and Aging Revolution Health & Wellness Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment npj Aging FOXO4 DRI FOXO4 p53 Interaction Blocker MedChemExpress
Pay in 4 interest-free payments of $6.48 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6



